Biomarkers you can count on

Multi-omics for precision medicine

Unlock clinical success

Elevating trials with biomarker insight from Codetta

Recognizing the significance of fluid biomarkers and their role in disease progression and therapy response is crucial for the success of clinical trials. Identifying and selecting biomarkers during the pre-clinical stages can lead to a 164% higher success rate in Phase II-III clinical trials.


Your translational program with rapid fluid biomarker analysis

Uncover a Multitude of Insights from a Single Sample. Experience DNA, RNA, and Protein Analysis for faster, more sensitive results with proven PCR technology, multiplexed for more comprehensive answers.

Introducing the

Codetta Bio Platform

One instrument, One workflow, comprehensive answers
Transforming Timelines, Efficiency and Savings with the Codetta Solution

benefits icon

Multi-omics & Multiplexed

Transform time-saving: Cut analysis time from 2 Days to Just 2 Hours, allowing for faster decision-making and more efficient processes.

benefits icon

Enhanced Sensitivity

Combining the precision of digital PCR with the dynamic range of qPCR enables multiplex biomarker measurement at fM levels.

benefits icon

Rapidly Customizable

Replace separate instruments with one all-in-one solution. A single, multifunctional instrument reduces the need for multiple tools, streamlining workflows, reducing costs, and saving space.

benefits icon

Easy to Adopt

Adopt a fully-integrated workflow with a simple setup and two- to three-hour assay run time.

One instrument, one Workflow, Comprehensive answers

“Our strategy is to develop an integrated platform that redefines multi-omics and sets a new standard of capability in the mid-plex translational research and clinical markets.”


Jacques Corriveau
CEO, Codetta BioTM


Advancing biomarker detection & multiplexing capabilities

About Us

Our team has been diligently working to establish a new standard in research and diagnostic capabilities. Comprising dedicated employees and key opinion leaders spanning various industries and specializations — from academic labs to the biopharma sector — we eagerly anticipate unveiling a future where multiplex biomarker measurements are seamlessly integrated into a single powerful platform.